Investor Relations

Home
Investor Relations
Important Notice

Announcement

CX-5461 IND submitted for combination therapy with SanofiRegeneron's approved PD-1 inhibitor Cemiplimab to treat refractory MSS CRC colorectal cancer

Download

Sep: 16; 2025

Notice of the 2025 Annual Shareholders’ Meeting

Meeting Title: 2025 Annual Shareholders’ Meeting
Date and Time: Wednesday, June 25, 2025, at 10:00 AM (Check-in starts at 9:30 AM)
Venue: Conference Room, 2nd Floor, No. 223, Section 3, Beixin Road, Xindian District, New Taipei City (International Conference Center)

Jun: 24; 2025